ArticleBMC health services research2025

Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China.

Bingying Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.